As preclinical data exist to supports activity of PI3K targeted agents on the immune microenvironment, the goal of this study was to assess the impact of Akt inhibition on the TME of HR+/HER2− BC in samples collected in a pre-surgical clinical trial. The gene discussed is AKT1; the disease is breast cancer.